The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
The Senate Health, Education, Labor & Pensions Committee today held a hearing to examine how primary care affects health care costs and outcomes.
Insights and Analysis
Grand Rapids, Mich.-based Spectrum Health makes remote consultations available via mobile carts in 34 medical specialties, and Columbus (Neb.) Community…
Headline
AHA staff participated this afternoon in a Rural Health Summit convened by Health and Human Services Secretary Alex Azar and Health Resources and S
Headline
The Center for Medicare and Medicaid Innovation today announced a new
Headline
The Centers for Medicare…
Headline
Commenting today on proposed policy changes for Medicare Advantage plan years 2020 and 2021, AHA expressed strong support for the Centers for Medicare…